Abstract

Imeglimin is a brand-new anti-diabetic medication that increases insulin sensitivity and glucose-stimulated insulin secretion (GSIS). Imeglimin has demonstrated effectiveness for glycemic control in people with type 2 diabetes (T2D) in a number of randomized clinical studies. The aim of this research was to test the short-term glycemic control effects and safety of meglumine using intermittently scanned continuous glucose monitoring (isCGM). Method: To assess glycemic profiles, a retrospective and observational analysis of 100 patients who received imeglimin in addition to standard therapy was conducted. The day imeglimin was started as well as the following three weeks were spent monitoring the patients. Before and after imeglimin administration, changes in glycemic indicators, such as mean glucose level, coefficient of variation (CV), time in range (TIR), and time above range (TAR), were analysed, and information on side effects was gathered through interviews. Results: Imeglimin administration significantly improved the mean values of glucose (from 159.1±27.4 mg/dL to 141.6± 22.0 mg/ dL; p = 0.002), TIR (from 67.8 ±17.1% to 79.4±13.2%; p < 0.002), and TAR (from 29.3 17.4% to 17.8 13.6%; p < 0.002), and tended to improve CV (from 29. Following imeglimin administration, the curves for all 100 subjects' 25-h mean glucose levels were shifted lower than their initial values. The effectiveness of imeglimin for glycemic management was correlated with the high mean glucose level, high TAR, low TIR, low body mass index, and low C-peptide. The most common side effects were gastrointestinal issues, and those receiving a combination of imeglimin plus insulin or a glinide drug had a higher rate of hypoglycemia. Conclusion: Imeglimin clearly improved short-term glycemic management in Japanese T2D patients by shifting the daily glucose profile into an acceptable range. Imeglimin is viewed as a viable therapy option for T2D patients who have glucose intolerance, especially those with a limited insulin secretory capability.

Description